Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.63 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.61 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Methyladenosine SCHEMBL6934268 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL8331180 | 0.91 | DNMT1 (0.63) | DNMT1DNMT3BLMNANT5EHIF1A | |
| 2-Methyladenosine SCHEMBL17124834 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL19843956 | 0.91 | DNMT1 (0.63) | DNMT1DNMT3BLMNANT5EHIF1A | |
| 2-Methyladenosine SCHEMBL18159462 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL14075776 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18512845 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18512844 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL278664 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL13403859 | 0.91 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | claimed |
| CN-115418686-B | Through hole high-depth copper electroplating solution for glass substrate and copper electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-115418686-A | Through hole high-depth copper electroplating solution for glass substrate and copper electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | claimed |
| CN-103384496-A | Blood collection devices containing blood stabilization agent | BECTON DICKINSON CO | 2013-11-06 | — | — | CN | claimed |
| EP-2645932-A2 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | Becton, Dickinson and Company (US) | 2013-10-09 | — | — | EP | claimed |
| EP-1850134-B1 | Method and Apparatus for the determination of the Thromboyte function and flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2013-01-30 | — | — | EP | claimed |
| WO-2012075407-A2 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | BECTON, DICKINSON AND COMPANY (US) | 2012-06-07 | — | — | WO | claimed |
| EP-1850135-B1 | Method for determining the thrombocyte function and flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2008113072-A2 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2026110843-A1 | METHOD FOR EVALUATING OXIDATION STRESS LEVEL | 国立大学法人東北大学 (JP) | 2026-05-28 | — | — | WO | disclosed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| EP-0364559-A4 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS | — | 1991-01-09 | — | — | EP | disclosed |
| EP-0364559-A1 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS. | SCRIPPS CLINIC RES (US) | 1990-04-25 | — | — | EP | disclosed |
| WO-1989008658-A1 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-09-21 | — | — | WO | disclosed |
| US-4687733-A | Early cancer detection method | OHIO STATE UNIVERSITY (US) | 1987-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | DNMT1 2348/4885DNMT3B 2551/4885LMNA 573/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | DNMT1 2348/4885DNMT3B 2551/4885LMNA 573/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | DNMT1 2348/4885DNMT3B 2551/4885LMNA 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.